"FDA remains committed to facilitating the development and approval of additional safe and effective therapies for adults with obesity or overweight." Experts have called the drug a "game changer ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...

The FDA recently approved Zepbound, a weekly injectable drug targeted to treat obesity. The medication contains tirzepatide, the same active ingredient that is also present in the diabetes drug ...

The US Food and Drug Administration (FDA) has approved the obesity treatment tirzepatide (Zepbound, Eli Lilly) for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...

Ozempic was first approved to treat diabetes in Canada seven years ago. Now the largest study of its kind suggests it and ...

The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...

The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity -- the first medication ...

Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things ...

Zepbound is the first prescription drug approved specifically to treat the common condition. By Dani Blum The Food and Drug Administration on Friday approved the weight loss drug Zepbound to treat ...

On Dec. 20, the FDA announced that the agency has approved Eli Lilly’s Zepbound (tirzepatide) to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. The drug is to be ...

The governor also said she would work with other states to leverage their combined purchasing power to reduce the cost of the ...